Norden Group LLC Makes New $230,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Norden Group LLC bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 262 shares of the biopharmaceutical company’s stock, valued at approximately $230,000.

A number of other institutional investors and hedge funds have also made changes to their positions in REGN. Annis Gardner Whiting Capital Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $26,000. Fortitude Family Office LLC acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth $31,000. MCF Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 12 shares in the last quarter. Criterion Capital Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $37,000. Finally, Sutton Wealth Advisors Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 38.2% in the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 13 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $903.48 on Thursday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The company has a market cap of $99.17 billion, a P/E ratio of 26.00, a price-to-earnings-growth ratio of 2.55 and a beta of 0.17. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33. The firm’s 50 day simple moving average is $944.78 and its 200-day simple moving average is $895.25.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping the consensus estimate of $10.73 by $1.13. The firm had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company’s quarterly revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the company posted $10.96 EPS. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.86 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on REGN shares. Truist Financial reaffirmed a “buy” rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. TD Cowen upped their price target on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Sanford C. Bernstein began coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price objective for the company. Finally, Barclays raised their price objective on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 23rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $977.77.

Insiders Place Their Bets

In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $982.05, for a total transaction of $98,205.00. Following the completion of the sale, the director now directly owns 18,282 shares in the company, valued at $17,953,838.10. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $982.05, for a total value of $98,205.00. Following the transaction, the director now directly owns 18,282 shares of the company’s stock, valued at $17,953,838.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bonnie L. Bassler sold 854 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, February 26th. The shares were sold at an average price of $979.25, for a total value of $836,279.50. Following the sale, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,353,323.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,095 shares of company stock worth $9,664,476. 8.83% of the stock is currently owned by company insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.